Strong dermatology sales for Spain's Almirall, which is looking for M&A deals

9 May 2016

Spain’s largest drugmaker Almirall (ALM: MC) this morning released financials for the first quarter of 2016,showing that total revenues were down 7.5% at 201 million euros compared with the like 2015 period. The company’s shares edged up 1.3% to 13.93 euros by mid-morning.

Net sales, however, were up 2.7% at 184.9 million euros. Gross were 3.2% higher at 130.3 million euros (70.5% of net sales) versus 126.2 million euros in the first quarter of 2015 (70.1% of net sales) due to the strong improvement in the product mix in the first part of the year.

Earnings before interest and taxes (EBIT) and EBIT, depreciation and amortization (EBITDA) were32.4 million euros and 54.8 million euros, down 25%. Other income of 16.1 million euros was significantly lower than 2015 due to the AstraZeneca milestone linked to AB (aclidinium bromide) combo launch in the European Union in first-quarter 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK